Expanded access to abiraterone acetate for men with mCRPC in UK

According to a BBC News report earlier today, abiraterone acetate has been approved for use by National Health Service (NHS) patients with metastic, castration-resistant prostate cancer (mCRPC) in Northern Ireland. A decision about availability of the drug in Scotland is expected on August 13. Abiraterone is already available to NHS patients in England and in Wales.

One Response

  1. This is good news for men in Northern Ireland, and hopefully the Scottish SMC will follow the rest of the UK. I think the SMC has been negotiating with the manufacturers to get a better deal on price as NICE did when they reconsidered approval for abiraterone.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: